21 jun: Odico A/S justerer forventningerne til årets resultat.
21 jun: Anmodning om suspension af handel i SKAGENs fonde
21-06-2019 09:00:00

Zealand Pharma introduces new website to support people living with short bowel syndrome

Press release – No. 15 / 2019

Zealand Pharma introduces new website to support people living with short bowel syndrome

  • LivingWithSBS.com is a new website with information about short bowel syndrome, drawing from experiences shared by SBS patients to support others living with the disease

     

  • Zealand Pharma is dedicated to supporting people living with SBS by also developing next generation peptide therapeutics and working to continuously improve the standard of care

Copenhagen, June 21, 2019 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today launched a new website dedicated to supporting people with short bowel syndrome (SBS).

The website leverages the stories and experiences of several patients and their families, as a way to focus on key aspects of living with SBS. Elements of personal insight, what to expect from available medical care and inspiration for achieving intestinal rehabilitation are intended to help SBS patients improve management of the disease for a better everyday quality of life.

Medical contributors includes Professor David F. Mercer, MD, PhD, University of Nebraska Medical Center (Omaha), and Professor Kishore R. Iyer, MBBS, FRCS, the Mount Sinai Hospital (New York). These field experts provide educational disease information, including explanation of the circumstances arising from short bowel disease and available treatment options.

“The rarity of SBS makes it an ‘orphan disease’. Medical expertise in SBS is in short supply, and desperate patients and their families often end up going from pillar to post, searching for expert teams. Our aim is to empower patients to talk with their medical teams, to continuously improve the treatment and management options for living with short bowel syndrome,” said Professor Kishore R. Iyer, MBBS, FRCS, from the Mount Sinai Hospital in New York. “When someone has SBS, their entire family lives and copes with the disease. We want to extend resources and support to this entire community, and LivingWithSBS.com can help as a launch point.”

“Launching the new website, LivingWithSBS.com, is an ideal way to connect members of the short bowel syndrome community,” said Michael Hall, Senior Vice President of Clinical and Medical Affairs at Zealand Pharma. “The personal stories shared by people living with SBS reveal the extreme burdens of the disease, while also offering support and encouragement for other patients and their families to seek optimal management and treatment.”

Visit LivingWithSBS.com to learn more about short bowel syndrome, and hear the stories from several patients and their families who successfully manage the disease in everyday life.

For further information, please contact:

Emmanuel Dulac, President and Chief Executive Officer

Tel.: +45 50 60 36 36, e-mail: edu@zealandpharma.com

Lani Pollworth Morvan, Investor Relations and Communication

Tel.: +45 50 60 37 78, e-mail: lpm@zealandpharma.com

About short bowel syndrome (SBS)

SBS is a complex chronic and severe condition associated with reduced or complete loss of intestinal function. Many patients have to be connected to infusion lines and pumps every day, which pose significant restrictions on their ability to engage in daily activities. In addition, they are at risk of experiencing a number of serious and life-threatening complications such as sepsis, blood clots, liver damage and renal impairment.

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.  

Attachment

Z_ID_ORG_FINAL_w_name_rgb_NEW2.jpg

Relateret indhold
20 sep - 
Aktier/middag: Rentemelding fra Jyske Bank sender banka..
20 sep - 
Aktier/åbning: Banker fortsætter op efter Jyskes nye re..
20 sep - 
Aktier/tendens: Novo Nordisk får markedet til at holde ..
Relateret debat
13:51 - 
Skal vi ikke lige se dit flere år gamle kursmål på + 40..
13:21 - 
"Der må komme en korrektion hvor opsamling bliver..
12:50 - 
Selv om jeg ikke bryder mig om dem som sorter og muligh..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
20 sep
ZEAL
Det amerikanske investeringshus Guggenheim Securities har indledt dækning af det danske biotekselska..
10
17 sep
ZEAL
Stiger stille og roligt. Tror det har givet en stor ro i investorkredse, at hollænderne lige smed 1/..
7
20 sep
ZEAL
Zealand Pharma: Briter skruer op for sats på kursfaldDet britiske investeringsselskab Marshall Wace ..
4
17 sep
ZEAL
Jep, tillykke til jer som holdt fast i den 👍
3
12:50
ZEAL
Selv om jeg ikke bryder mig om dem som sorter og muligheden i det hele taget, så er det vel et fornu..
1
20 sep
ZEAL
Har ikke meget forstand på shorting, men kunne man ikke tænke sig, at det i virkeligheden er en fors..
1
20 sep
ZEAL
Spændende om den bryder igennem eller skal konsolidere først.   Området er i ATH. Long term: Dobbelt..
1

OECD sænker global vækstprognose for de kommende år

19-09-2019 11:20:24
Organisationen for Økonomisk Samarbejde og Udvikling (OECD) sænker sin globale vækstprognose for de kommende år, idet organisationen nu ser yderligere risici i verdensøkonomien.OECD venter nu en global vækst i bruttonationalproduktet (BNP) på 2,9 pct. i år og 3,0 pct. næste år.Det er en nedrevidering fra henholdsvis 3,2 pct. og 3,4 pct. i den seneste prognose.For USA er vækstprognosen sænket til 2..

Aktier/tendens: Udsigt til rød start ovenpå FED-møde

19-09-2019 08:25:07
Der er umiddelbart udsigt til små fald fra starten af den danske aktiehandel torsdag, hvor øjne og ører kan rette sig mod Ørsted, Simcorp og Sydbank. Dermed følger markedet onsdagens tendens efter tilbagegang efter rentemødet i den amerikanske centralbank, Federal Reserve (Fed).Japanske aktier ligger højere, futures på amerikanske aktier ligger op til 0,4 pct. lavere, mens DAX-futuren ligger 0,1 p..

Lars Christensens Verden - Episode 26: Sidste uges quant quake varsler nye tider på de finansielle markeder

Relaterede nyheder
18-09-2019 19:17:00
Begivenheden er af nogle blevet omtalt som et jordskælv i de globale markeder, og nej det var ikke ECB's seneste rentebeslutning eller den renteforhøjelse eller -nedsættelse, Fed annoncerer onsdag aften, dansk tid. Det er heller ikke oliepriserne, der har bevæget sig voldsomt ovenpå weekendens angreb på de saudiske olieinstallationer og Trumps Iran-tweets i kølvandet herpå, men derimod det såkaldt..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Zealand Pharma A/S 169,10 0,4% Stigning i aktiekurs
Zealand Pharma Aktiesels.. 169,10 0,4% Stigning i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
22. september 2019 18:18:32
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190829.2 - EUROWEB6 - 2019-09-22 18:18:32 - 2019-09-22 18:18:32 - 1 - Website: OKAY